DK0835137T3 - Indkapslede celler, som danner viruspartikler - Google Patents

Indkapslede celler, som danner viruspartikler

Info

Publication number
DK0835137T3
DK0835137T3 DK96923905T DK96923905T DK0835137T3 DK 0835137 T3 DK0835137 T3 DK 0835137T3 DK 96923905 T DK96923905 T DK 96923905T DK 96923905 T DK96923905 T DK 96923905T DK 0835137 T3 DK0835137 T3 DK 0835137T3
Authority
DK
Denmark
Prior art keywords
encapsulated cells
virus particles
form virus
cells
genes
Prior art date
Application number
DK96923905T
Other languages
English (en)
Inventor
Robert Michael Saller
Walter H Guenzburg
Brian Salmons
Original Assignee
Bavarian Nordic As
Gsf Forschungszentrum Umwelt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0835137(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bavarian Nordic As, Gsf Forschungszentrum Umwelt filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK0835137T3 publication Critical patent/DK0835137T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DK96923905T 1995-06-27 1996-06-24 Indkapslede celler, som danner viruspartikler DK0835137T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK74095 1995-06-27

Publications (1)

Publication Number Publication Date
DK0835137T3 true DK0835137T3 (da) 2006-03-06

Family

ID=8097001

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96923905T DK0835137T3 (da) 1995-06-27 1996-06-24 Indkapslede celler, som danner viruspartikler

Country Status (22)

Country Link
US (1) US6776985B1 (da)
EP (1) EP0835137B1 (da)
JP (2) JP4119952B2 (da)
KR (1) KR100484883B1 (da)
CN (1) CN1187095C (da)
AT (1) ATE309000T1 (da)
AU (1) AU708273B2 (da)
CA (1) CA2222559A1 (da)
CZ (1) CZ286979B6 (da)
DE (1) DE69633180D1 (da)
DK (1) DK0835137T3 (da)
ES (1) ES2253754T3 (da)
HK (1) HK1010139A1 (da)
IL (1) IL122119A (da)
NO (1) NO321427B1 (da)
NZ (1) NZ312671A (da)
PL (1) PL185338B1 (da)
PT (1) PT835137E (da)
RU (1) RU2187301C2 (da)
SI (1) SI0835137T1 (da)
UA (1) UA65525C2 (da)
WO (1) WO1997001357A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0817858T3 (da) 1995-03-09 2003-08-11 Gsf Forschungszentrum Umwelt Vektorer, som indeholder terapeutiske gener for antimikrobielle peptider, til anvendelse ved genterapi
AU708273B2 (en) 1995-06-27 1999-07-29 Bavarian Nordic A/S Encapsulated cells producing viral particles
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
RU2223788C2 (ru) 1996-03-27 2004-02-20 Бавариан Нордик Рисерч Инститьют А/С Трансдуцирующие цитохром p450 ретровирусные векторы
WO1999056660A1 (en) 1998-05-05 1999-11-11 Koninklijke Philips Electronics N.V. Toothbrush comprising a brush member having a bristle field and an interdental bristle field
CN1950397B (zh) 2004-03-30 2012-05-16 Ns基因公司 生长因子NsG33的治疗用途
CA2606858A1 (en) 2005-05-03 2006-11-09 Veterinarmedizinische Universitat Wien Permeable capsules
AU2008343193B2 (en) 2007-12-20 2014-04-24 Ethicon, Incorporated Encapsulated kidney tissue
KR101250925B1 (ko) * 2011-10-28 2013-04-04 한화케미칼 주식회사 캡슐 세포용 구조체
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
ES2939617T3 (es) * 2015-11-24 2023-04-25 Glaxosmithkline Ip Dev Ltd Líneas celulares estables para producción retroviral
DE102016122317A1 (de) * 2015-11-24 2017-05-24 Glaxosmithkline Intellectual Property Development Limited Transientes transfektionsverfahren für retrovirale produktion
WO2017205573A1 (en) 2016-05-25 2017-11-30 Lonza Houston Inc. Methods for isolating adeno-associated virus using a polydiallyldialkylammonium salt
RU2688383C2 (ru) * 2017-07-10 2019-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Способ синтеза белка в культуре бактериальных клеток
CN110615667B (zh) * 2018-06-19 2022-02-15 华北理工大学 基于铁尾矿和碱渣的核壳结构陶粒及其制备方法
JP2024519909A (ja) * 2021-05-21 2024-05-21 バイオナット ラブス リミテッド マイクロボット媒介治療送達のためのシステム及び方法
CN115820683B (zh) * 2022-09-28 2024-04-05 西南大学 家蚕Cyp9a20基因及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
DD160393A3 (de) * 1980-11-14 1983-07-27 Horst Dautzenberg Mikrokapseln und verfahren zu ihrer herstellung
US4686098A (en) * 1984-05-14 1987-08-11 Merck & Co., Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
EP0199362A3 (en) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System and apparatus for delayed and pulsed release of biologically active substances
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
DE68927089T2 (de) 1988-05-17 1997-04-03 Sloan Kettering Inst Cancer Retroviraler vektor
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE4021050A1 (de) * 1990-06-29 1992-01-02 Akad Wissenschaften Ddr Verfahren zur herstellung von mikrokapseln
CA2051288C (en) * 1990-09-14 2002-02-05 Robert L. Martuza Viral targeted destruction of neoplastic cells
WO1992010564A1 (en) * 1990-12-13 1992-06-25 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
JP4037446B2 (ja) 1994-09-02 2008-01-23 ゲーエスエフ − フォルシュンクスツェントルム・フューア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー 非自己不活化性の発現標的化レトロウイルスベクタ
AU708273B2 (en) 1995-06-27 1999-07-29 Bavarian Nordic A/S Encapsulated cells producing viral particles
ES2174103T3 (es) 1995-09-06 2002-11-01 Austrian Nordic Biotherapeutic Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
RU2223788C2 (ru) 1996-03-27 2004-02-20 Бавариан Нордик Рисерч Инститьют А/С Трансдуцирующие цитохром p450 ретровирусные векторы

Also Published As

Publication number Publication date
WO1997001357A1 (en) 1997-01-16
RU2187301C2 (ru) 2002-08-20
AU708273B2 (en) 1999-07-29
CA2222559A1 (en) 1997-01-16
PL185338B1 (pl) 2003-04-30
US6776985B1 (en) 2004-08-17
UA65525C2 (en) 2004-04-15
PL324289A1 (en) 1998-05-11
IL122119A0 (en) 1998-04-05
NZ312671A (en) 1999-10-28
JP2008101011A (ja) 2008-05-01
KR19990028491A (ko) 1999-04-15
IL122119A (en) 2004-06-01
NO975813L (no) 1998-02-23
EP0835137B1 (en) 2005-11-09
ATE309000T1 (de) 2005-11-15
JP4848348B2 (ja) 2011-12-28
CN1189104A (zh) 1998-07-29
HK1010139A1 (en) 1999-06-17
AU6415496A (en) 1997-01-30
CN1187095C (zh) 2005-02-02
SI0835137T1 (sl) 2006-04-30
CZ419597A3 (cs) 1998-03-18
ES2253754T3 (es) 2006-06-01
JP4119952B2 (ja) 2008-07-16
PT835137E (pt) 2004-12-31
JPH11508768A (ja) 1999-08-03
EP0835137A1 (en) 1998-04-15
DE69633180D1 (de) 2004-09-23
CZ286979B6 (en) 2000-08-16
NO321427B1 (no) 2006-05-08
KR100484883B1 (ko) 2005-09-02
NO975813D0 (no) 1997-12-10

Similar Documents

Publication Publication Date Title
DK0835137T3 (da) Indkapslede celler, som danner viruspartikler
CA2092195A1 (en) Retroviral packaging cell line
CA2154023A1 (en) Recombinant infectious non-segmented negative strand rna virus
DE69435316D1 (de) Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren
WO1991002805A3 (en) Recombinant retroviruses delivering vector constructs to target cells
ES2075901T3 (es) Sistemas de expresion de virus recombinantes de arn con cadena negativa y vacunas.
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
DE59410380D1 (de) Endosomolytisch wirksame partikel
WO1996013597A3 (en) Improved adenovirus and methods of use thereof
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
MY123970A (en) Catalyst component comprising magnesium, titanium, a halogen and an electron donor, its preparation and use
GB9020586D0 (en) Recombinant retroviruses
DE69420034T2 (de) Synthetische mischpeptide, die die entstehung von neutralisierenden antikörpern und die wirkung der cytotoxischen t-lymphozyten gegen hiv hervorufen
AU6704496A (en) Helper viruses for the preparation of recombinant viral vectors
EP1006196A3 (de) Retrovirale, mit LCMV-Glykoprotein pseudotypisierte Hybrid-Vektoren
AU1022999A (en) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
DK0843731T3 (da) Adenovirusvektorer til genterapi
CA2263790A1 (en) Method for immortalizing cells
RU2006123079A (ru) Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы
YU48200A (sh) Farmaceutski preparati
NZ507942A (en) Viral chimeras comprised of CAEV and HIV-1 genetic elements
CA2331440A1 (en) Amphotropic retrovirus packaging cell line, process for its production and use thereof
FR2650954B1 (fr) Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida
JP2002513546A5 (da)
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants